Antiviral options for biodefense

Current Opinion in Virology

Volumn 3, Issue 5, 2013, Pages 537-541

  Byrd, Chelsea M ^a   Grosenbach, Douglas W ^a   Hruby, Dennis E ^a  

^a SIGA Technologies Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYNOJIRIMYCIN; 1 RIBOFURANOSYL 3 ETHYNYL[1,2,4]TRIAZOLE; 1,2,4 TRIAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ARESTVYR; BENZAMIDE DERIVATIVE; CASTANOSPERMINE 6 BUTYRATE; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; FAVIPIRAVIR; FGI 103; LJ 001; MORPHOLINO OLIGONUCLEOTIDE; NSC 6291; RIBAVIRIN; SMALLPOX VACCINE; ST 148; ST 193; TECOVIRIMAT; UNCLASSIFIED DRUG; UV 4;

ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; ARENAVIRUS; ARTICLE; BIOLOGICAL WARFARE; BUNYAVIRUS; CLINICAL TRIAL (TOPIC); DENGUE; DISEASE PREDISPOSITION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; EBOLA HEMORRHAGIC FEVER; FLAVIVIRUS INFECTION; FOOD AND DRUG ADMINISTRATION; HEMORRHAGIC FEVER; HUMAN; IMMUNITY; IMMUNIZATION; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RISK FACTOR; SMALLPOX; SMALLPOX VIRUS; THREAT; VACCINIA; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; BIOTERRORISM; COMMUNICABLE DISEASE CONTROL; HUMANS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); PUBLIC HEALTH; UNITED STATES; VIRUS DISEASES;

EID: 84886887288     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.05.020     Document Type: Review

References (37)

1. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: new estimates of drug development costs J Health Econ 22 2003 151 185 (Pubitemid 36279392)
2. R. Jordan, J.M. Leeds, S. Tyavanagimatt, and D.E. Hruby Development of ST-246(R) for treatment of poxvirus infections Viruses 2 2010 2409 2435
3. D.W. Grosenbach, R. Jordan, and D.E. Hruby Development of the small-molecule antiviral ST-246 as a smallpox therapeutic Future Virol 6 2011 653 671
4. G. Yang, D.C. Pevear, M.H. Davies, M.S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, and S. Tohan An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge J Virol 79 2005 13139 13149 (Pubitemid 41433232)
5. A. Berhanu, D.S. King, S. Mosier, R. Jordan, K.F. Jones, D.E. Hruby, and D.W. Grosenbach ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation Antimicrob Agents Chemother 53 2009 4999 5009
6. E. Sbrana, R. Jordan, D.E. Hruby, R.I. Mateo, S.Y. Xiao, M. Siirin, P.C. Newman, A.P. DAR, and R.B. Tesh Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection Am J Trop Med Hyg 76 2007 768 773 (Pubitemid 351627722)
7. J. Huggins, A. Goff, M. Eric, N. Twenhafel, J. Chapman, M. Tate, R. Jordan, T. Bolken, and D. Hruby Successful treatment in the monkeypox and variola primate models of smallpox by the oral drug ST-246 Antiviral Res 74 2007 A35
8. S.K. Smith, J. Self, S. Weiss, D. Carroll, Z. Braden, R.L. Regnery, W. Davidson, R. Jordan, D.E. Hruby, and I.K. Damon Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus J Virol 85 2011 9176 9187
9. D.W. Grosenbach, A. Berhanu, D.S. King, S. Mosier, K.F. Jones, R.A. Jordan, T.C. Bolken, and D.E. Hruby Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice Proc Natl Acad Sci U S A 107 2010 838 843
10. J. Huggins, A. Goff, L. Hensley, E. Mucker, J. Shamblin, C. Wlazlowski, W. Johnson, J. Chapman, T. Larsen, and N. Twenhafel Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246 Antimicrob Agents Chemother 53 2009 2620 2625
11. R. Jordan, D. Tien, T.C. Bolken, K.F. Jones, S.R. Tyavanagimatt, J. Strasser, A. Frimm, M.L. Corrado, P.G. Strome, and D.E. Hruby Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor Antimicrob Agents Chemother 52 2008 1721 1727 (Pubitemid 351614665)
12. J. Chinsangaram, K.M. Honeychurch, S.R. Tyavanagimatt, J.M. Leeds, T.C. Bolken, K.F. Jones, R. Jordan, T. Marbury, J. Ruckle, and D. Mee-Lee Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers Antimicrob Agents Chemother 56 2012 4900 4905
13. J. Chinsangaram, K.M. Honeychurch, S.R. Tyavanagimatt, T.C. Bolken, R. Jordan, K.F. Jones, T. Marbury, I. Lichtenstein, M. Pickens, and M. Corrado Pharmacokinetic comparison of a single oral dose of polymorph form I versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers Antimicrob Agents Chemother 56 2012 3582 3586
14. R. Jordan, J. Chinsangaram, T.C. Bolken, S.R. Tyavanagimatt, D. Tien, K.F. Jones, A. Frimm, M.L. Corrado, M. Pickens, and P. Landis Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects Antimicrob Agents Chemother 54 2010 2560 2566
15. D.C. Quenelle, M.N. Prichard, K.A. Keith, D.E. Hruby, R. Jordan, G.R. Painter, A. Robertson, and E.R. Kern Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses Antimicrob Agents Chemother 51 2007 4118 4124 (Pubitemid 350057813)
16. S. Vora, I. Damon, V. Fulginiti, S.G. Weber, M. Kahana, S.L. Stein, S.I. Gerber, S. Garcia-Houchins, E. Lederman, and D. Hruby Severe eczema vaccinatum in a household contact of a smallpox vaccinee Clin Infect Dis 46 2008 1555 1561 (Pubitemid 351706737)
17. E.R. Lederman, W. Davidson, H.L. Groff, S.K. Smith, T. Warkentien, Y. Li, K.A. Wilkins, K.L. Karem, R.S. Akondy, and R. Ahmed Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001 J Infect Dis 206 2012 1372 1385
18. E. Marris Dramatic rescue relieves rare case of smallpox infection Nat Med 13 2007 517 (Pubitemid 46828462)
19. E. Lederman, R. Miramontes, J. Openshaw, V.A. Olson, K.L. Karem, J. Marcinak, R. Panares, W. Staggs, D. Allen, and S.G. Weber Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: an investigation of potential fomites in the home environment Vaccine 27 2009 375 377
20. J.B. McCormick, I.J. King, P.A. Webb, C.L. Scribner, R.B. Craven, K.M. Johnson, L.H. Elliott, and R. Belmont-Williams Lassa fever. Effective therapy with ribavirin N Engl J Med 314 1986 20 26 (Pubitemid 16183064)
21. J.R. Burgeson, A.L. Moore, D.N. Gharaibeh, R.A. Larson, N.R. Cerruti, S.M. Amberg, D.E. Hruby, and D. Dai Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles Bioorg Med Chem Lett 23 2013 750 756
22. D. Dai, J.R. Burgeson, D.N. Gharaibeh, A.L. Moore, R.A. Larson, N.R. Cerruti, S.M. Amberg, T.C. Bolken, and D.E. Hruby Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole Bioorg Med Chem Lett 23 2013 744 749
23. K.A. Cashman, M.A. Smith, N.A. Twenhafel, R.A. Larson, K.F. Jones, R.D. Allen 3rd, D. Dai, J. Chinsangaram, T.C. Bolken, and D.E. Hruby Evaluation of Lassa antiviral compound ST-193 in a guinea pig model Antiviral Res 90 2011 70 79
24. B.W. Neuman, L.H. Bederka, D.A. Stein, J.P. Ting, H.M. Moulton, and M.J. Buchmeier Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors Antimicrob Agents Chemother 55 2011 4631 4638
25. B.B. Gowen, M.H. Wong, K.H. Jung, A.B. Sanders, M. Mendenhall, K.W. Bailey, Y. Furuta, and R.W. Sidwell In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections Antimicrob Agents Chemother 51 2007 3168 3176 (Pubitemid 350067524)
26. J.M. Rusnak, W.R. Byrne, K.N. Chung, P.H. Gibbs, T.T. Kim, E.F. Boudreau, T. Cosgriff, P. Pittman, K.Y. Kim, and M.S. Erlichman Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea Antiviral Res 81 2009 68 76
27. G.J. Mertz, L. Miedzinski, D. Goade, A.T. Pavia, B. Hjelle, C.O. Hansbarger, H. Levy, F.T. Koster, K. Baum, and A. Lindemulder Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America Clin Infect Dis 39 2004 1307 1313 (Pubitemid 39458516)
28. D.H. Chung, S.C. Kumarapperuma, Y. Sun, Q. Li, Y.K. Chu, J.B. Arterburn, W.B. Parker, J. Smith, K. Spik, and H.N. Ramanathan Synthesis of 1-beta-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus Antiviral Res 79 2008 19 27
29. M.C. Wolf, A.N. Freiberg, T. Zhang, Z. Akyol-Ataman, A. Grock, P.W. Hong, J. Li, N.F. Watson, A.Q. Fang, and H.C. Aguilar A broad-spectrum antiviral targeting entry of enveloped viruses Proc Natl Acad Sci U S A 107 2010 3157 3162
30. S. Bhatt, P.W. Gething, O.J. Brady, J.P. Messina, A.W. Farlow, C.L. Moyes, J.M. Drake, J.S. Brownstein, A.G. Hoen, and O. Sankoh The global distribution and burden of dengue Nature 2013
31. C.M. Byrd, D. Dai, D.W. Grosenbach, A. Berhanu, K.F. Jones, K.B. Cardwell, C. Schneider, K.A. Wineinger, J.M. Page, and C. Harver A novel inhibitor of dengue virus replication that targets the capsid protein Antimicrob Agents Chemother 2012
32. S.T. Perry, M.D. Buck, E.M. Plummer, R.A. Penmasta, H. Batra, E.J. Stavale, K.L. Warfield, R.A. Dwek, T.D. Butters, and D.S. Alonzi An iminosugar with potent inhibition of dengue virus infection in vivo Antiviral Res 98 2013 35 43
33. J.L. Miller, R. Lachica, A.C. Sayce, J.P. Williams, M. Bapat, R. Dwek, P.R. Beatty, E. Harris, and N. Zitzmann Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo Antimicrob Agents Chemother 56 2012 6379 6386
34. S. Watanabe, A.P. Rathore, C. Sung, F. Lu, Y.M. Khoo, J. Connolly, J. Low, E.E. Ooi, H.S. Lee, and S.G. Vasudevan Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial Antiviral Res 96 2012 32 35
35. R.G. Panchal, S.P. Reid, J.P. Tran, A.A. Bergeron, J. Wells, K.P. Kota, J. Aman, and S. Bavari Identification of an antioxidant small-molecule with broad-spectrum antiviral activity Antiviral Res 93 2012 23 29
36. T.K. Warren, K.L. Warfield, J. Wells, S. Enterlein, M. Smith, G. Ruthel, A.S. Yunus, M.S. Kinch, M. Goldblatt, and M.J. Aman Antiviral activity of a small-molecule inhibitor of filovirus infection Antimicrob Agents Chemother 54 2010 2152 2159
37. T.K. Warren, K.L. Warfield, J. Wells, D.L. Swenson, K.S. Donner, S.A. Van Tongeren, N.L. Garza, L. Dong, D.V. Mourich, and S. Crumley Advanced antisense therapies for postexposure protection against lethal filovirus infections Nat Med 16 2010 991 994